Related Experiment Videos
Horse-chestnut seed extract for chronic venous insufficiency. A criteria-based systematic review
1Department of Complementary Medicine, School of Postgraduate Medicine and Health Sciences, University of Exeter, United Kingdom.
Insights
Horse-chestnut seed extract (HCSE) effectively treats chronic venous insufficiency (CVI), reducing leg swelling and symptoms like pain and fatigue. It is superior to placebo and as effective as other treatments.
Area of Science:
- Pharmacology
- Phytotherapy
- Vascular Medicine
Background:
- Chronic venous insufficiency (CVI) affects a significant portion of the adult population, leading to discomfort and reduced quality of life.
- Current treatments for CVI include compression therapy, lifestyle modifications, and various pharmaceutical agents.
- Horse-chestnut seed extract (HCSE) has been traditionally used for venous disorders, but robust evidence for its efficacy in CVI was needed.
Purpose of the Study:
- To systematically evaluate the scientific evidence supporting the use of horse-chestnut seed extract (HCSE) for symptomatic relief in patients with chronic venous insufficiency (CVI).
Main Methods:
- Comprehensive literature searches were conducted across multiple databases (MEDLINE, EMBASE, BIOSIS, CISCOM, Cochrane Library) up to December 1996.
- Included studies were double-blind, randomized controlled trials (RCTs) investigating oral HCSE for CVI patients.
- Data extraction and methodological quality assessment were performed independently by two reviewers.
Main Results:
- Placebo-controlled studies consistently demonstrated the superiority of HCSE in reducing lower-leg volume and circumference.
- HCSE significantly alleviated subjective symptoms such as leg pain, itching, fatigue, and tenseness.
- Comparative trials indicated HCSE is as effective as O-(beta-hydroxyethyl)-rutosides and potentially equivalent to compression therapy, with mild, infrequent adverse effects.
Conclusions:
- Horse-chestnut seed extract (HCSE) is a viable and effective treatment option for chronic venous insufficiency (CVI).
- Evidence supports HCSE's efficacy in improving both objective measures and subjective symptoms of CVI.
- HCSE offers a favorable risk-benefit profile, making it a noteworthy consideration for CVI management.
Objective:
To assess the evidence for or against horse-chestnut seed extract (HCSE) as a symptomatic treatment of chronic venous insufficiency (CVI).
Data Sources:
Computerized literature searches were performed in MEDLINE, EMBASE, BIOSIS, CISCOM, and the Cochrane Library (all from their respective institution to December 1996). The search terms were "horse chestnut," "Aesculus hippocastanum," "escin," and "Rosskastanie" (German for "horse chestnut"). There were no restrictions on the language of publication.
Study Selection:
Double-blind, randomized controlled trials of oral HCSE for patients with CVI were included. Identifiers were removed from all publications before assessment.
Data Extraction:
Data were extracted in a standardized, predefined manner. Trial outcomes and the methodological quality of each trial were independently assessed by the 2 reviewers.
Data Synthesis:
The superiority of HCSE is suggested by all placebo-controlled studies. The use of HCSE is associated with a decrease of the lower-leg volume and a reduction in leg circumference at the calf and ankle. Symptoms such as leg pain, pruritus, and a feeling of fatigue and tenseness are reduced. Five comparative trials against the reference medication indicate that HCSE and O-(beta-hydroxyethyl)-rutosides are equally effective. One trial suggests a therapeutic equivalence of HCSE and compression therapy. Adverse effects are usually mild and infrequent.
Conclusions:
These data imply that HCSE is superior to placebo and as effective as reference medications in alleviating the objective signs and subjective symptoms of CVI. Thus, HCSE represents a treatment option for CVI that is worth considering.